Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2002

View Archived Issues

Drug pipeline for anxiety

Thalidomide plus temozolomide in malignant gliomas

Good tolerability profile reported for tetracycline COL-3 in high-grade glioma

EMD-121794 reported to be well tolerated in patients with malignant gliomas

Enzyme-inducing anticonvulsants improve tolerability of CCI-779 in patients with CNS tumors

Improved tolerability of PZA in glioblastoma multiforme patients receiving anticonvulsants

Tolerability of intratumoral DTI-015 in recurrent malignant glioma

T-138067 inactive in astrocytoma and glioblastoma multiforme

Promising data reported for dendritic cell vaccine in GBM

Boston Scientific acquires Smart Therapeutics

Bayer describes inhibitors of PDE7B for asthma and bone disorders

Novel nicotinic acetylcholine and/or 5-HT receptor ligands covered by Merck patent

Two series of cytokine production inhibitors with utility in arthritis and heart failure

New CRF antagonists under study at GSK

BMS designs new series of PDE7 inhibitors

Sankyo scientists prepare benzopyran compounds with multiple mechanisms of action

Senju claims novel compounds with potential in reflux esophagitis

Encouraging results from phase II trial with IP-751 in neuropathic pain

Solvay acquires exclusive worldwide rights to cetrorelix

Preclinical efficacy of Cerebragel in brain cancer

Organon and Entelos expand research collaboration

FDA approves Pegasys and Copegus combination therapy in hepatitis C

Swissmedic approves Glivec for first-line treatment of CML

Celltech returns rights to CF program to Targeted Genetics

Allos to begin rolling NDA submission for RSR-13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...